Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 3/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1546666 | 0.86 | MAPT (0.45) | MAPTPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL1945724 | 0.83 | ATM (0.48) | MAPTPOLBPDE4AADORA2APDE4B | |
| SCHEMBL1946776 | 0.82 | MAPT (0.43) | MAPTPOLBPDE4AADORA2APDE4B | |
| SCHEMBL1546783 | 0.81 | ALDH1A1 (0.42) | MAPTPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL1945849 | 0.79 | ALDH1A1 (0.40) | MAPTPOLBPDE4AADORA2APDE4B | |
| SCHEMBL2328928 | 0.77 | MAPT (0.47) | MAPTPOLBPDE4AADORA2APDE4B | |
| SCHEMBL1546118 | 0.77 | ALDH1A1 (0.49) | POLBPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL1945124 | 0.77 | ALDH1A1 (0.46) | MAPTPOLBPDE4AADORA2APDE4B | |
| SCHEMBL1943263 | 0.77 | ALDH1A1 (0.35) | MAPTPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL1946059 | 0.76 | ALDH1A1 (0.51) | MAPTPOLBALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8324224-B2 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2465859-A1 | 8-Triazolylxanthine derivatives, processes for their production and their use as adenosine receptor antagonists | Life & Brain GmbH (DE) | 2012-06-20 | — | — | EP | disclosed |
| EP-2465859-A1 | 8-Triazolylxanthine derivatives, processes for their production and their use as adenosine receptor antagonists | Life & Brain GmbH (DE) | 2012-06-20 | — | — | EP | disclosed |
| WO-2012076974-A1 | 8-TRIAZOLYLXANTHINE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS | LIFE & BRAIN GMBH (DE) | 2012-06-14 | — | — | WO | disclosed |
| US-20110257127-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| EP-1444233-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD PALO ALTO INC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20110130362-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7795269-B2 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100222300-A1 | A2B Adenosine Receptor Antagonists | GILEAD PALO ALTO, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20050261316-A1 | A2B Adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050101778-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050038045-A1 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2004106337-A1 | XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-6825349-B2 | PURINE DERIVATIVES FOR TREATMENT OF GASTROINTESTINAL DISORDERS, IMMUNOLOGICAL DISORDERS, NEUROLOGICAL DISORDERS | CV THERAPEUTICS INC. | 2004-11-30 | — | — | US | disclosed |
| EP-1444233-A2 | A 2B? ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20030229106-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030139428-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2003042214-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-05-22 | — | — | WO | disclosed |
| EP-0386683-A2 | Xanthine derivatives having bronchodilating activity, a process for the preparation thereof and pharmaceutical compositions containing them | POLI INDUSTRIA CHIMICA S.p.A. (IT) | 1990-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257127-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | MAPT 4833/4885POLB 1152/4885PDE4A 49/4885 |
| US-20050038045-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | MAPT 4833/4885POLB 1152/4885PDE4A 49/4885 |
| US-20050101778-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | MAPT 4244/4885POLB 1350/4885PDE4A 75/4885 |
| US-20100222300-A1 | A2B Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | MAPT 4833/4885POLB 1152/4885PDE4A 49/4885 |
| US-20030139428-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | MAPT 4828/4885POLB 1115/4885PDE4A 29/4885 |
| US-20030229106-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | MAPT 4828/4885POLB 1115/4885PDE4A 29/4885 |
| US-20050261316-A1 | A2B Adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | MAPT 4833/4885POLB 1152/4885PDE4A 49/4885 |
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | MAPT 4833/4885POLB 1152/4885PDE4A 49/4885 |
| US-20110130362-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | MAPT 4833/4885POLB 1152/4885PDE4A 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.